The DOI matches its Crossref record; 209 of the 209 references it cites were found in a registry or an index.
Gastrointestinal Stromal Tumors
Open accessAbstract
GI stromal tumors (GISTs) are neoplasms with a varying malignancy potential ranging from virtually indolent tumors to rapidly progressing cancers. GISTs occur throughout the intestinal tract, and most harbor an activating mutation in either KIT or platelet-derived growth factor A ( PDGFRA). Diagnosis is made using immunohistochemistry, but molecular testing with mutation analysis is paramount for selection of appropriate therapy. Most small GISTs are cured with surgery. Tyrosine kinase inhibitor (TKI) therapy has led to substantial improvements in survival, both for patients with localized GIST and those with advanced disease. Adjuvant therapy with imatinib benefits patients with a high risk of recurrence, with studies suggesting most benefit with at least 3 years of therapy. Neoadjuvant imatinib therapy should be considered for patients requiring extensive surgery, aiming at shrinking the tumor to allow organ preservation and less extensive surgery. The following three TKIs have been approved for the management of advanced disease: imatinib, sunitinib, and regorafenib; imatinib is usually the best tolerated of the three and the standard first-line treatment. TKIs benefit the majority of patients with advanced GIST but have no or limited efficacy in patients with the PDGFRA D842V mutation or patients with GIST lacking KIT and PDGFRA mutations. Surgery, the mainstay of primary tumor management, also plays a role in the advanced disease setting for selected patients, as do some other approaches such as palliative radiation therapy. Research continues to identify novel therapies, in particular effective agents to treat TKI-refractory disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–209 of 209
Tsujimura, T. (1996) · Pathology International · doi:10.1111/j.1440-1827.1996.tb03571.x · Cited by 43
Nakatani, H., Kobayashi, M., Jin, T., Taguchi, T., Sugimoto, T., Nakano, T., Hamada, S., & Araki, K. (2005) · Cancer Science · doi:10.1111/j.1349-7006.2005.00018.x · Cited by 43
Management of Resectable Gastrointestinal Stromal Tumor
Chaudhry, U. I., & DeMatteo, R. P. (2009) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2009.01.001 · Cited by 41
Molecular Targets in Gastrointestinal Stromal Tumors (GIST) Therapy
Braconi, C., Bracci, R., & Cellerino, R. (2008) · Current Cancer Drug Targets · doi:10.2174/156800908785133169 · Cited by 41
Schmieder, M., Henne‐Bruns, D., Mayer, B., Knippschild, U., Rolke, C., Schwab, M. G., & Kramer, K. M. (2016) · Frontiers in Pharmacology · doi:10.3389/fphar.2016.00504 · Cited by 37
Nemoto, H., Tate, G., Schirinzi, A., Suzuki, T., SASAYA, S., Yoshizawa, Y., Midorikawa, T., Mitsuya, T., Dallapiccola, B., & Sanada, Y. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-006-1772-7 · Cited by 34
Merten, L., Agaimy, A., Moskalev, E. A., Giedl, J., Kayser, C., Geddert, H., Schaefer, I., Cameron, S., Werner, M., Ströbel, P., et al. (2016) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqw193 · Cited by 31
Genetics of Gastrointestinal Stromal Tumors
Patil, D. T., & Rubin, B. P. (2015) · Surgical pathology clinics · doi:10.1016/j.path.2015.05.006 · Cited by 26
Patil, D. T., Ma, S., Konishi, M., Carver, P. D., Pukay, M., Beadling, C., Corless, C. L., & Rubin, B. P. (2015) · American Journal of Clinical Pathology · doi:10.1309/ajcprk3v2eiiupqz · Cited by 12
Cited by
Gastrointestinal stromal tumours
Blay, J.-Y., Kang, Y.-K., Nishida, T., & von Mehren, M. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00254-5 · Cited by 460
Self-citationNacev, B. A., Sanchez-Vega, F., Smith, S. A., Antonescu, C. R., Rosenbaum, E., Shi, H., Tang, C., Socci, N. D., Rana, S., Gularte-Mérida, R., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30453-x · Cited by 232
Metadata
- Authors
- von Mehren, M., & Joensuu, H.
- Venue
- Journal of Clinical Oncology
- Published
- 2018-01-10
- Volume
- 36
- Issue
- 2
- Pages
- 136-143
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2772513551
- Cited by
- 306
- References
- 209
- FWCI
- 16.19
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.